COR earnings analysis
What we found in COR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cencora, Inc. reported robust Q2 results for FY26, with revenue of $78.4 billion, a 3.8% increase from the prior year, though slightly missing the consensus estimate of $80.98 billion. The notable E.P.S. of $8.40 significantly exceeded the expected $4.74, bolstered by a 17.3% increase in gross profit, driven primarily by growth in both U.S. and International Healthcare Solutions segments. Management also raised its adjusted EPS guidance for FY26 from $17.45-$17.75 to $17.65-$17.90, showcasing confidence in future performance despite elevated operating expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q2 Revenue Grows to $78.4 Billion
- Revenue increased by $2.9 billion, or 3.8%, from the prior year, driven by growth in both segments.
- E.P.S. Significantly Beats Estimates
- Reported E.P.S. of $8.40 surpassed the consensus estimate of $4.74.
- Strong Gross Profit Growth
- Gross profit rose by $528.5 million, or 17.3%, signaling improved efficiency and segment performance.
- U.S. Healthcare Solutions Revenue Up 2.9%
- U.S. segment revenue increased by $1.9 billion, primarily driven by specialty product sales.
- International Segment Revenue Surges
- International Healthcare Solutions revenue increased by 13.0%, primarily from growth in Europe.
- Adjusted EPS Guidance Raised
- Management raised the fiscal 2026 EPS guidance to $17.65-$17.90 from a previous $17.45-$17.75.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Expenses
- Total operating expenses rose by $422.1 million, or 20.9%, from the prior year.
- High Interest Expense
- Interest expense increased by $36.5 million, or 35.1%, primarily due to new debt financing for acquisitions.
- Regulatory Compliance Challenges
- Potential risks from regulatory environments have been highlighted as a continuing concern impacting business.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $8.4
- Gross margin
- 4.58%
- Operating margin
- 1.45%
- Segment
- U.S. Healthcare Solutions: $68.77 billion
- Segment
- International Healthcare Solutions: $7.57 billion
- Segment
- Other: $2.06 billion
What they said about what is next.
Adjusted diluted EPS guidance raised from $17.45-$17.75 to $17.65-$17.90 for FY26.
The filing reads better than the one before it.
What came before.
- 10-K · November 25, 2025
- Cencora reported fiscal 2025 revenue of $321.3 billion, up $27.4 billion (9.3%) year-over-year driven by U.S. Healthcare Solutions growth and GLP-1 product volumes; operating income rose 20.8% to $2.63 billion while…
- 10-Q · January 31, 2024
- Cencora reported Q1 revenue of $72,252,833,000 (up 15.0% YoY) and diluted EPS of $2.98 (up $0.65 or 27.9% YoY). Gross profit increased to $2,468,812,000 while operating income rose to $822,875,000; operating cash flow…
- 10-K · November 21, 2023
- Cencora reported fiscal 2023 revenue of $262.173 billion, up $23.6 billion or 9.9% year-over-year, driven primarily by U.S. Healthcare Solutions. Gross profit rose 8.0% to $8.959 billion and diluted EPS increased to…
- 10-Q · February 1, 2023
- AmerisourceBergen reported quarter-over-quarter revenue and EPS growth: revenue of $62,846,832,000 and diluted EPS of $2.33, driven by higher gross profit and net income. Operating cash flow declined to $710,080,000 and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing COR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever